New Jersey is currently home to 1664 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
NCT05639543
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Rutgers-New Jersey Medical School, Newark, New Jersey
Conditions: Alcohol Associated Hepatitis
Register for Updates
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
NCT05318573
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Atlantic Health System / Morristown Medical Center, Morristown, New Jersey
Conditions: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Register for Updates
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
NCT05308264
Recruiting
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Oncology Clinical Research Referral Office, Hackensack, New Jersey
Conditions: Low Risk Myelodysplastic Syndromes
Register for Updates
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Research Site, East Brunswick, New Jersey
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Smartphones for Opiate Addiction Recovery
NCT05033028
Recruiting
Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates the numerical probability that a patient will reuse illicit opiates within the next 7-10 days.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/09/2025
Locations: Rutgers University, Piscataway, New Jersey
Conditions: Opioid-use Disorder
Register for Updates
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
NCT04774419
Recruiting
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activites), Basking Ridge, New Jersey
Conditions: Endometrial Cancer
Register for Updates
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
NCT00539162
Recruiting
The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk.
Gender:
FEMALE
Ages:
Between 50 years and 74 years
Trial Updated:
04/08/2025
Locations: Carol G. Simon Cancer Center / Atlantic Health, Morristown, New Jersey
Conditions: Ovarian Cancer
Register for Updates
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
NCT06261957
Recruiting
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: GSK Investigational Site, Jersey City, New Jersey
Conditions: Asthma
Register for Updates
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120
Recruiting
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocar... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Englewood Health, Englewood, New Jersey
Conditions: Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Register for Updates
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
NCT03909412
Recruiting
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
Register for Updates
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
NCT05918692
Recruiting
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Acute Myeloid Leukemia
Register for Updates
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)
NCT05818150
Recruiting
This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are randomized to treatment with either genicular artery embolization (GAE) using Embosphere Microspheres or steroid injection over a period of 24 months.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/03/2025
Locations: Atlantic Medical Imaging, Galloway, New Jersey
Conditions: Knee Osteoarthritis
Register for Updates